ClinicalTrials.gg
CompletedNCT06559007Updated Mar 18, 2025

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

A Phase 1 interventional study of HRS-5041 dose level 1 and HRS-5041 dose level 2 in Prostate Cancer, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 14 open to participants now, 17 under way, 4 of them phase 3. Prostatic Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
24th of 31
24 · median 69
Started
2024
with 2 others
Phase 1
14 of 31
6 open now
Registered
19th of 31
by date

Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 24th largest by enrollment, is one of 3 that started in 2024, is one of 14 in phase 1, and was the 19th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a phase 1, open-label, randomized study. The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.

Read the detailed description

The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Caucasian participants;
  2. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial,
  3. Male aged between 18 to 55 years of age (inclusive) at the date of signed consent form.
  4. Total body weight ≥ 50.0 kg, (BMI) between 19.0 and 32.0 kg/m2 (inclusive) at screening.

Exclusion criteria

Exclusion Criteria:

  1. History of receiving any androgen receptor (AR) degraders.
  2. History or evidence of
  3. History of severe abnormal gastric emptying, severe gastrointestinal (GI) disease, or participants who had GI surgeries (except GI polypectomy).
  4. Severe infections, injuries, or major surgeries as determined by the investigator within 6 months
  5. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Experimental: HRS-5041 dose level 1

    Sing dose level 1

    Drug: HRS-5041 dose level 1

  • Experimental
    Experimental: HRS-5041 dose level 2

    Sing dose level 2

    Drug: HRS-5041 dose level 2

Interventions

  • Single dose of HRS-5041 orally administered

    Also known as: HRS-5041 (single dose, oral administration, dose level 1)

  • Single dose of HRS-5041 orally administered

    Also known as: HRS-5041 (single dose, oral administration, dose level 2)

06

What researchers measure

Primary outcomes

  1. PK profile (Cmax) of HRS-5041 after a single oral (PO) administration:

    Parameters: Cmax

    Time frame: Day 10

  2. PK profile (AUC0-t) of HRS-5041 after a single oral (PO) administration:

    Parameter: AUC0-t

    Time frame: Day 10

  3. PK profile (AUC0-inf) of HRS-5041 after a single oral (PO) administration:

    Parameter:AUC0-inf

    Time frame: Day 10

  4. PK profile (Tmax) of HRS-5041 after a single oral (PO) administration:

    Parameter: Tmax

    Time frame: Day 10

  5. PK profile ( t1/2) of HRS-5041 after a single oral (PO) administration:

    Parameter: t1/2

    Time frame: Day 10

  6. PK profile (CL/F) of HRS-5041 after a single oral (PO) administration:

    Parameter: CL/F

    Time frame: Day 10

  7. PK profile (Vz/F) of HRS-5041 after a single oral (PO) administration:

    Parameter: Vz/F

    Time frame: Day 10

Secondary outcomes

  1. Safety and tolerability - number and severity of adverse events

    Incidence and severity of AE

    Time frame: Day 10

  2. Safety and tolerability - Blood pressure

    Incidence of Adverse Events and Abnormalities as assessed by blood pressure (systolic and diastolic pressure)

    Time frame: Day 10

  3. Safety and tolerability - Body temperature

    Incidence of Adverse Events and Abnormalities as assessed by body temperature

    Time frame: Day 10

  4. Safety and tolerability - Physical examination

    Incidence of Adverse Events and Abnormalities as Assessed by Physical Examination

    Time frame: Day 10

  5. Safety and tolerability - Laboratory tests

    Number of abnormalities assessed based on safety bloods and urine test

    Time frame: Day 10

  6. Safety and tolerability - ECG

    heart rate, PR interval, QT interval, corrected QT (QTcF using Fridericia's formula) interval, and QRS

    Time frame: Day 10

07

Study locations

1 site
  • Nucleus Network Melbourne
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2025, 3 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 3 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 19, 2024
StartActual
Sep 25, 2024
Primary completionActual
Jan 6, 2025
CompletionActual
Mar 3, 2025
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06559007
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Sep 25, 2024
Primary completion
Jan 6, 2025
Completion
Mar 3, 2025
Last update
Mar 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5041

Start the discussion